Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is financially sound with increasing revenues and a diverse portfolio of ophthalmic pharmaceutical products. Through potential catalysts like new code for IOPIDINE and updated clinical data for IHEEZO, as well as strategic plans for expanding sales of VEVYE, the company shows strong potential for growth in the future. However, they face industry risks that could impact their success, so continued monitoring is necessary.

Bears say

Harrow is facing challenges such as a recovery of lower year-over-year revenue expected in the short term due to the buildup of inventory in 4Q25. Additionally, growing pains within both Iheezo and Vevye, while problematic, represent a high demand for the drugs and a likely long-term solution for cataract surgery. However, changes in the company's business rules may affect new patient starts, and the unexpected $8M hit on Vevye is concerning. While management's reiteration of guidance for 2026 shows a slight increase at the higher end, it is still a bear to base case estimate, indicating a relatively weak financial performance.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.